Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transfusional Iron Overload”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Testing effectiveness (Phase 2)Study completedNCT00940602
What this trial is testing

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Study completedNCT02125877
What this trial is testing

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Who this might be right for
Chronic Iron Overload Due to Transfusion-dependant Anemias
Novartis Pharmaceuticals 173
Testing effectiveness (Phase 2)Ended earlyNCT00602446
What this trial is testing

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Who this might be right for
Breast CancerIron OverloadLeukemia+5 more
Masonic Cancer Center, University of Minnesota 4
Large-scale testing (Phase 3)Study completedNCT00235391
What this trial is testing

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Who this might be right for
ThalassemiaSickle Cell DiseaseDiamond Blackfan Anemia+1 more
Novartis Pharmaceuticals 1,683
Testing effectiveness (Phase 2)Study completedNCT01044186
What this trial is testing

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Who this might be right for
Transfusional Iron Overload
Novartis Pharmaceuticals 30
Testing effectiveness (Phase 2)Study completedNCT01186419
What this trial is testing

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

Who this might be right for
Transfusional Iron OverloadBeta-thalassemia
Shire 51
Testing effectiveness (Phase 2)Study completedNCT00395629
What this trial is testing

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Who this might be right for
Iron OverloadHereditary Hemochromatosis
Novartis Pharmaceuticals 49
Not applicableStudy completedNCT01369719
What this trial is testing

Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload

Who this might be right for
ThalassemiaIron OverloadTransfusion Related Complications
Hormozgan University of Medical Sciences 138
Testing effectiveness (Phase 2)Ended earlyNCT01363908
What this trial is testing

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Who this might be right for
Transfusional Iron OverloadBeta-Thalassemia
Shire 30
Testing effectiveness (Phase 2)Study completedNCT00600938
What this trial is testing

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Who this might be right for
Transfusional Iron OverloadTransfusional Hemosiderosis
Novartis Pharmaceuticals 197
Large-scale testing (Phase 3)Study completedNCT00171171
What this trial is testing

Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Who this might be right for
Beta-ThalassemiaHemosiderosis
Novartis 252
Large-scale testing (Phase 3)UnknownNCT01511848
What this trial is testing

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Who this might be right for
Beta-thalassemia MajorSickle Cell DiseaseIron Hemosiderosis
Ain Shams University 60
Post-approval studies (Phase 4)Study completedNCT00481143
What this trial is testing

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Who this might be right for
Myelodysplastic SyndromesTransfusion Dependent Iron Overload
Novartis Pharmaceuticals 63
Post-approval studies (Phase 4)Study completedNCT01335035
What this trial is testing

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Who this might be right for
Iron Overload
Novartis Pharmaceuticals 30
Post-approval studies (Phase 4)Study completedNCT01250951
What this trial is testing

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Who this might be right for
Myelodysplastic SyndromeThalassemia
Novartis Pharmaceuticals 111
Post-approval studies (Phase 4)Study completedNCT00171301
What this trial is testing

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

Who this might be right for
Beta-thalassemia MajorHemosiderosisIron Overload+1 more
Novartis Pharmaceuticals 233
Testing effectiveness (Phase 2)Study completedNCT00067080
What this trial is testing

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Who this might be right for
Anemia, Sickle Cell
Novartis Pharmaceuticals 195
Post-approval studies (Phase 4)Ended earlyNCT01326845
What this trial is testing

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Who this might be right for
Myelodysplastic SyndromeTransfusional Iron Overload
Novartis Pharmaceuticals 12
Post-approval studies (Phase 4)Study completedNCT00654589
What this trial is testing

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Who this might be right for
Iron Overload
Novartis Pharmaceuticals 75
Testing effectiveness (Phase 2)Study completedNCT00390858
What this trial is testing

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Who this might be right for
Transfusional Iron Overloadβ-thalassemia MajorPediatric Rare Anemia
Novartis Pharmaceuticals 40
Load More Results